Dosing & Uses
Hepatocellular Carcinoma
Pending FDA approval for first-line treatment of unresectable hepatocellular carcinoma in combination with rivoceranib
Next:
Pharmacology
Mechanism of Action
Monoclonal antibody that targets checkpoint inhibitor PD-1 (programmed death 1) and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2, releasing the PD-1 pathway-mediated inhibition of the immune response, including antitumor immune response, thereby decreasing tumor growth
Binding of PD-L1 and PD-L2 to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
